• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Tempus AI Inc.

    2/10/26 5:10:29 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    TEMPUS AI, INC.

    (Name of Issuer)


    Class A Common Stock, $0.0001 Par Value Per Share

    (Title of Class of Securities)


    88023B103

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    88023B103


    1Names of Reporting Persons

    Eric Paul Lefkofsky
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,478,213.00
    6Shared Voting Power

    41,289,784.00
    7Sole Dispositive Power

    1,478,213.00
    8Shared Dispositive Power

    41,289,784.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    42,767,997.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    24.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    88023B103


    1Names of Reporting Persons

    Blue Media, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    21,053,773.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    21,053,773.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    21,053,773.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    88023B103


    1Names of Reporting Persons

    Gray Media, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,974,783.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,974,783.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,974,783.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    88023B103


    1Names of Reporting Persons

    Lefkofsky Family 2025 GRAT
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ILLINOIS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TEMPUS AI, INC.
    (b)Address of issuer's principal executive offices:

    600 West Chicago Avenue, Suite 510, Chicago, IL, 60654.
    Item 2. 
    (a)Name of person filing:

    Eric Paul Lefkofsky ("Mr. Lefkofsky") Blue Media, LLC ("Blue Media") Gray Media, LLC ("Gray Media") Lefkofsky Family 2025 GRAT (the "GRAT", and together with Mr. Lefkofsky, Blue Media and Gray Media, the "Reporting Persons") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    c/o Tempus AI, Inc. 600 West Chicago Avenue, Suite 510 Chicago, IL 60654
    (c)Citizenship:

    Individuals: Mr. Lefkofsky - United States Entities: Blue Media - Delaware Gray Media - Delaware Lefkofsky Family 2025 GRAT - Illinois
    (d)Title of class of securities:

    Class A Common Stock, $0.0001 Par Value Per Share
    (e)CUSIP No.:

    88023B103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Mr. Lefkofsky beneficially owns 42,767,997 shares which consists of: (i) 1,440,713 shares of the Issuer's Class A Common Stock, (ii) 37,500 shares of the Issuer's Class A Common Stock issuable upon the vesting of restricted stock units within 60 days of December 31, 2025, (iii) 206 shares of the Issuer's Class A Common Stock held by Black Media, LLC ("Black Media"), (iv) 16,188,469 shares of the Issuer's Class A Common Stock held by Blue Media, (v) 8,974,783 shares of the Issuer's Class A Common Stock held by Gray Media, (vi) 832,131 shares of the Issuer's Class A Common Stock held by Lefkofsky Family Foundation DTD 9/5/06 Eric Lefkofsky TTEE (the "Foundation"), (vii) 406 shares of the Issuer's Class A Common Stock held by 346 Long LLC, (viii) 10,000,000 shares of the Issuer's Class A Common Stock held by the GRAT, (ix) 250,000 shares of the Issuer's Class A Common Stock held by Vas.org Foundation, (x) 178,485 shares of the Issuer's Class A Common Stock issuable upon conversion of 178,485 shares of the Issuer's Class B Common Stock held by Black Media, (xi) 4,865,304 shares of the Issuer's Class A Common Stock issuable upon conversion of 4,865,304 shares of the Issuer's Class B Common Stock held by Blue Media. Mr. Lefkofsky is the sole manager of each of Black Media, Blue Media and Gray Media and a member of, and controls a limited liability company that is a member of, 346 Long LLC. Mr. Lefkofsky and his wife, Elizabeth Lefkofsky, serve as trustees of the Foundation. Mr. Lefkofsky serves as the trustee of Vas.org Foundation, and Ms. Lefkofsky serves as the trustee of the GRAT. Mr. Lefkofsky holds shared voting and dispositive power of the securities reported herein. Blue Media beneficially owns 21,053,773 shares which consists of: (i) 16,188,469 shares of the Issuer's Class A Common Stock held by Blue Media and (ii) 4,865,304 shares of the Issuer's Class A Common Stock issuable upon conversion of 4,865,304 shares of the Issuer's Class B Common Stock held by Blue Media. Mr. Lefkofsky is the sole manager of Blue Media and shares voting and dispositive power of the securities reported herein. Gray Media beneficially owns 8,974,783 shares of Class A Common Stock. Mr. Lefkofsky is the sole manager of Gray Media and shares voting and dispositive power of the securities reported herein. The GRAT beneficially owns 10,000,000 shares of Class A Common Stock. Ms. Lefkofsky serves as the trustee of the GRAT.
    (b)Percent of class:

    Mr. Lefkofsky owns 24.0% of Class A Common Stock and 24.0% of combined Common Stock. Blue Media owns 11.8% of Class A Common Stock and 11.8% of combined Common Stock. Gray Media owns 5.2% of Class A Common Stock and 5.0% of combined Common Stock. The GRAT owns 5.8% of Class A Common Stock and 5.6% of combined Common Stock. These percentages are calculated based upon (i) 173,235,428 shares of the Issuer's Class A Common Stock and (ii) 5,043,789 shares of the Issuer's Class B Common Stock outstanding as of December 31, 2025, as provided by the Issuer. In addition, calculation of the percentage of Class A Common Stock beneficially owned by each Reporting Person includes shares of Class A Common Stock issuable upon conversion of shares of Class B Common Stock beneficially owned by such Reporting Person, which are treated as converted into Class A Common Stock only for the purpose of computing the Class A Common Stock beneficial ownership percentage of such Reporting Person. Calculation of the percentages of Class A Common Stock and combined Common Stock beneficially owned by each Reporting Person also includes shares of the Issuer's Class A Common Stock issuable upon the vesting of restricted stock units within 60 days of December 31, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Sole power to vote or to direct the vote: See responses to Item 5 on the attached cover pages.

     (ii) Shared power to vote or to direct the vote:

    Shared power to vote or to direct the vote: See responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    Sole power to dispose or to direct the disposition of: See responses to Item 7 on the attached cover pages.

     (iv) Shared power to dispose or to direct the disposition of:

    Shared power to dispose or to direct the disposition of: See responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Eric Paul Lefkofsky
     
    Signature:/s/ Eric Paul Lefkofsky
    Name/Title:Eric Paul Lefkofsky
    Date:02/10/2026
     
    Blue Media, LLC
     
    Signature:/s/ Eric Paul Lefkofsky
    Name/Title:Eric Paul Lefkofsky, Manager
    Date:02/10/2026
     
    Gray Media, LLC
     
    Signature:/s/ Eric Paul Lefkofsky
    Name/Title:Eric Paul Lefkofsky, Manager
    Date:02/10/2026
     
    Lefkofsky Family 2025 GRAT
     
    Signature:/s/ Elizabeth Lefkofsky
    Name/Title:Elizabeth Lefkofsky, Trustee
    Date:02/10/2026
    Exhibit Information

    Exhibit 99.1 - Joint Filing Agreement

    Get the next $TEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    12/2/2025$85.00Overweight
    Morgan Stanley
    10/21/2025$88.00Buy → Hold
    TD Cowen
    10/20/2025$110.00Buy
    Canaccord Genuity
    9/2/2025$90.00Buy
    H.C. Wainwright
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    More analyst ratings

    $TEM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Tempus AI Inc.

    SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)

    2/10/26 5:10:29 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    1/28/26 4:21:30 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Tempus AI, Inc. (0001717115) (Filer)

    1/12/26 6:05:18 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

    2/10/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

    New study published in Nature Communications builds on Ambry's contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), today announced its contribution to new research leveraging Multiplexed Assays of Variant Effect (MAVEs) studies to advance interpretation of hereditary cancer-linked genetic variants, published in Nature Communications. Led by researchers at Leiden University Medical Center in the Netherlands and supported by Ambry's extensive clinical data, this study revealed previously unfounded missense path

    2/4/26 7:00:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

    Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the company's commitment to diagnostic accuracy. A decade ago, in an industry first, Ambry Genetics pioneered paired DNA/RNA testing for hereditary cancer and continues to be among the only laboratories offering RNA testing insights across both hereditary cancer and exome testing. Ambry Genetics first implemented RNA testing in 2016 as part of a research and validation pilot and subseq

    2/2/26 7:00:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Epstein David R sold $21,982 worth of shares (370 units at $59.41), decreasing direct ownership by 1% to 26,051 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    2/4/26 4:30:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    CEO and Chairman Lefkofsky Eric P sold $10,899,207 worth of shares (166,250 units at $65.56) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    1/30/26 4:15:08 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Chief Operating Officer Fukushima Ryan sold $321,300 worth of shares (5,000 units at $64.26) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    1/7/26 6:25:17 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Morgan Stanley resumed coverage on Tempus AI with a new price target

    Morgan Stanley resumed coverage of Tempus AI with a rating of Overweight and set a new price target of $85.00

    12/2/25 8:35:17 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by TD Cowen with a new price target

    TD Cowen downgraded Tempus AI from Buy to Hold and set a new price target of $88.00

    10/21/25 7:15:53 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Canaccord Genuity initiated coverage on Tempus AI with a new price target

    Canaccord Genuity initiated coverage of Tempus AI with a rating of Buy and set a new price target of $110.00

    10/20/25 8:04:09 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Financials

    Live finance-specific insights

    View All

    Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

    2/10/26 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Third Quarter 2025 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

    10/21/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $TEM
    Leadership Updates

    Live Leadership Updates

    View All

    Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im

    11/5/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology